Technoderma Medicines Completes Positive Ph2a Proof- of Concept Trial with Topical TDM-180935 Ointment for Atopic Dermatitis
January 06, 2025 | 20:00
Technoderma Medicines, Inc., a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial of topical TDM-180935 ointment in patients with Atopic Dermatitis.
Mobile Version